<DOC>
	<DOC>NCT00204594</DOC>
	<brief_summary>Phase I/II clinical trial to analyze safety and efficiency of intralesional application of the bispecific single chain antibody rM28 and autologous PBMCs in patients with metastatic melanoma stage III/IV and unresectable metastasis.</brief_summary>
	<brief_title>Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28</brief_title>
	<detailed_description>Phase I/II clinical trial to analyze safety and efficiency of intralesional application of the bispecific single chain antibody rM28 and autologous PBMCs in patients with metastatic melanoma stage III/IV and unresectable metastasis. The antibody is directed against epitops of human CD28 and the melanoma associated surface antigen HMV-MAA. Treatment over 5 days with dose escalation.</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Bispecific</mesh_term>
	<criteria>malignant melanoma stage III/IV injectable soft tissue metastasis informed consent given Karnofsky &gt;= 70% additional chemotherapeutical treatment systemic glucocorticoids brain metestasis other malignancies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>mRNA</keyword>
	<keyword>vaccination</keyword>
	<keyword>melanoma</keyword>
</DOC>